Hepatitis B and C Testing: Windows, Accuracy, and Lab Panels

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are different viruses that both infect the liver. HBV spreads through blood, semen, and other bodily fluids — sexual contact is a recognized route, as is sharing injection equipment, and transmission from parent to child around birth is well documented. HCV is primarily blood-borne; in the United States, injection drug use has been a major driver, though sexual and other routes can also occur. Both are distinct from hepatitis A, which spreads mainly through contaminated food and water rather than sexual contact.

STDcheck's hepatitis menu covers hepatitis A, B, and C testing. Hepatitis B is the one most directly tied to sexual-health screening. Hepatitis C is included for completeness: it is a blood-borne infection with serious long-term liver consequences. Hepatitis A is available in panel form but is not an STI in the usual sense.

Acute hepatitis B is frequently mild or silent. Many people newly infected with HBV have no obvious symptoms, or only a flu-like illness easy to attribute to something else. Some clear the virus after acute infection; others develop chronic infection. Chronic hepatitis B is defined by persistence of hepatitis B surface antigen (HBsAg) for at least 6 months, and over years to decades it can lead to cirrhosis, liver failure, or liver cancer without monitoring and care.

Hepatitis C moves on a slower clock. Most people with acute HCV have no symptoms or only a mild illness, and infection often becomes chronic. CDC describes chronic hepatitis C as a serious condition that can progress silently to cirrhosis and liver cancer over years or decades. Because both viruses can simmer without dramatic symptoms, testing — not symptom-watching — is how infection is found.

As with HIV, window periods shape how results should be read. For hepatitis B, CDC's recommended adult screening is a triple panel: hepatitis B surface antigen (HBsAg), antibody to surface antigen (anti-HBs), and total core antibody (anti-HBc). HBsAg indicates current infection — acute or chronic — and can typically be detected within a few weeks of exposure; core antibodies appear with the immune response; surface antibodies mark recovery-related immunity or vaccination immunity. Because a recent infection can take up to six months or more to become fully apparent serologically, CDC advises retesting about six months after a known exposure.

For hepatitis C, the antibody test (anti-HCV) is first — but antibodies take time to develop. CDC reports that in acute HCV it usually takes 8 to 11 weeks for antibodies to become detectable, so an antibody test taken sooner after exposure can miss an early infection. That is why CDC guidance pairs antibody testing with nucleic acid testing (NAT) for HCV RNA: RNA can typically be detected within 1 to 2 weeks of exposure, and an RNA test confirms current infection when an antibody result is reactive. A reactive antibody with undetectable RNA can reflect a past infection that resolved, or a very early infection caught before antibodies appeared.

Practical takeaway: the test has to match the timing of the exposure. A very recent exposure may call for RNA-based detection; routine screening leans on antibody-based panels, with RNA confirmation whenever an antibody result is reactive.

Finding HBV or HCV early changes what happens next. With hepatitis B, diagnosis opens the door to monitoring and antiviral treatment that can suppress the virus over the long term and reduce liver-related risk; without care, chronic infection slowly wears on the liver. Hepatitis C is now treated with direct-acting antiviral medications that can clear HCV RNA from the blood in most people who complete a course of therapy — a transformation from the limited options that existed before these drugs. Linkage to a knowledgeable clinician turns a lab result into a management plan.

Hepatitis B vaccination is available and recommended. CDC recommends one-time triple-panel screening for all adults aged 18 and older, with vaccination offered to those found susceptible, and ACIP recommends vaccination across the lifespan, including for adults at increased risk. Vaccination is one of the clearest public-health success stories in viral hepatitis. For hepatitis C, no vaccine exists — testing, treatment when indicated, and harm-reduction practices such as not sharing injection equipment are the tools available.

CDC's 2023 viral hepatitis surveillance reported 2,214 acute hepatitis B cases — corresponding to an estimated 14,400 HBV infections after adjusting for underreporting — alongside 17,650 newly reported chronic hepatitis B cases and 1,769 hepatitis B-related deaths. For hepatitis C, 4,966 acute cases were reported, corresponding to an estimated 69,000 infections; 101,525 newly reported chronic cases and 11,194 hepatitis C-related deaths were also recorded.

CDC policy materials estimate that roughly 660,000 people in the United States are living with hepatitis B and about 2.4 million with hepatitis C — large pools of chronic infection, much of it not yet diagnosed, that annual case counts alone understate. Like herpes, hepatitis is not part of this site's four-disease metro dataset (chlamydia, gonorrhea, syphilis, and HIV), so no city-level hepatitis tables appear here; the figures above are national.

Hepatitis testing is laboratory-based: blood is drawn at a participating site and analyzed by a certified lab. Insurance often covers recommended screening — CDC recommends one-time triple-panel hepatitis B screening for all adults and hepatitis C screening for all adults aged 18 to 79 — but coverage rules vary. Many people also choose self-pay testing to keep ordering and results inside a confidential portal, independent of insurance claims.

STDcheck offers hepatitis A, B, and C testing as individual tests and panels. Hepatitis B options follow the serologic logic CDC describes (surface antigen and related markers); hepatitis C testing follows the antibody-first model, with the clinical standard of confirming reactive results with RNA. Choosing a single test versus a panel depends on the exposure question: a known sexual exposure points toward hepatitis B; a blood exposure or injection-history question may warrant including hepatitis C. No dollar figures appear here because pricing changes — current pricing lives on STDcheck's pricing page, linked from the call-to-action on this site.

Testing decisions belong with a healthcare professional who can place results in context. This page is educational and is not a substitute for medical advice.

Common questions about hepatitis B and C testing windows and what panel results mean.